Please ensure Javascript is enabled for purposes of website accessibility

Why Inovio Stock Is Crashing Today

By Keith Speights – Sep 28, 2020 at 10:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The planned phase 2/3 study of COVID-19 vaccine candidate INO-4800 just hit a major speed bump.

What happened

Shares of Inovio Pharmaceuticals (INO -10.05%) were crashing 32.5% lower as of 9:37 a.m. EDT on Monday. The huge decline came after the company announced that the U.S. Food and Drug Administration placed Inovio's filing to begin a phase 2/3 clinical study of COVID-19 vaccine candidate INO-4800 on partial clinical hold.

So what

Investors are justifiably worried about the status of Inovio's COVID-19 vaccine program. The small biotech had hoped to start its phase 2/3 study of INO-4800 in September. That's now completely off the table. 

Doctor wearing a mask holding hand up with palm forward

Image source: Getty Images.

There was one sliver of good news in Inovio's concerning announcement, though. The company stated that the FDA's partial clinical hold "is not due to the occurrence of any adverse events" in its ongoing phase 1 study of INO-4800. A serious safety issue for Inovio's COVID-19 vaccine candidate would have been about the worst news that Inovio could have had.

So why did the FDA choose to hold up the initiation of the phase 2/3 study of INO-4800? It's not totally clear at this point. Inovio only said that the agency "has additional questions" about the phase 2/3 study, which would include an evaluation of both INO-4800 and the Cellectra 2000 delivery device to be used in the clinical trial.

Monday's sell-off of the biotech stock isn't surprising. However, it could turn out to be overdone if the phase 2/3 study of INO-4800 isn't delayed for too long.

Now what

Inovio said that it's "actively working to address the FDA's questions and plans to respond in October." The FDA will then have up to 30 days after Inovio's response to determine if the phase 2/3 study of INO-4800 can begin. In the meantime, Inovio's phase 1 study of INO-4800 will continue, as will the company's other clinical trials. 

Inovio said that it and its partners are continuing to prepare for the phase 2/3 study of INO-4800. However, the initiation of the study isn't just dependent on an FDA resolution of the partial clinical hold. Inovio also stated that the launch of the phase 2/3 study is "subject to the receipt of external funding to conduct the trial."

Inovio has previously hinted that an announcement regarding external funding for its INO-4800 program could be made in September. However, it's uncertain whether or not this announcement will also be delayed.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Inovio Pharmaceuticals, Inc. Stock Quote
Inovio Pharmaceuticals, Inc.
INO
$1.66 (-10.05%) $0.18

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
342%
 
S&P 500 Returns
107%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/29/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.